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Revision of criteria for evaluation of clinical efﬁcacy
of antimicrobial agents on UTI (including the title
in the revised edition)
In the 1970s, clinicians and researchers specializing in
urinary tract infections (UTIs) established and published
the ﬁrst-ever Criteria for Clinical Evaluation of Drug
Efﬁcacy on UTI. There had so far been no uniform criteria
for the evaluation of drug efﬁcacy, and different criteria for
determining drug efﬁcacy had been used in the develop-
ment of drugs, which had caused problems in determining
drug efﬁcacy and had made it impossible to compare
efﬁcacy between drugs. To resolve these challenges, the
Criteria for Clinical Evaluation of Drug Efﬁcacy on UTI
were established on the basis of the results of a large
number of studies. The late Dr. Masaaki Ohkoshi, the late
Dr. Joji Ishigami, the late Dr. Tsuneo Nishiura, Dr.
Toyohei Machida, Dr. Yoshiaki Kumamoto, Dr. Joichi
Kumazawa, Dr. Yukimichi Kawada, Dr. Sadao Kamidono,
and other senior physicians made efforts to create the
world’s ﬁrst Criteria for Clinical Evaluation of Drug Efﬁ-
cacy on UTI, which had contributed enormously to the
development of antimicrobial agents for UTIs. In 1989, an
International Symposium entitled ‘‘Clinical Evaluation of
Drug Efﬁcacy on UTI’’ was held in Tokyo and offered
opportunities to get international recognition of the Criteria
for Clinical Evaluation of Drug Efﬁcacy on UTI. There-
after, the International UTI Symposium was established
and came to be held biennially in conjunction with the
International Congress on Chemotherapy. The joint sym-
posium has been held ten times to date.
In Japan, the Criteria for Evaluation of Clinical Efﬁcacy of
Antimicrobial Agents on UTI were created by the UTI study
group. The Criteria, which were those of the revised 3rd edi-
tion, involved various urological infections, including pros-
tatitis, epididymitis, and urethritis, in addition to UTIs.
Meanwhile, Infectious Diseases Society of America (IDSA)/
Food and Drug Administration (FDA) guidelines and the
Criteria for Clinical Evaluation of Drug Efﬁcacy were estab-
lished in theUnitedStates andEurope, respectively,which led
to an increased need for international harmonization aswell as
globalization of the development of antimicrobial agents. To
move with the times and to allow compatibility between data
accumulated in Japan and data fromother countries, the Study
Group on Urology, the Committee of Clinical Evaluation
Methods, and the Japanese Society of Chemotherapy dis-
cussed and created the 4th edition of Criteria for Evaluation of
Clinical Efﬁcacy of Antimicrobial Agents on UTI (tentative)
and its supplement in 1996.
However, further international harmonization was nee-
ded, as international drug development, extrapolation of
clinical data from other countries, and bridging studies
had been increasing. In bringing about international
M. Yasuda  S. Takahashi  H. Kiyota  K. Ishikawa 
A. Takahashi  S. Yamamoto  S. Arakawa  K. Monden 
T. Muratani  R. Hamasuna  H. Hayami  T. Matsumoto
UTI Subcommittee of the Clinical Evaluation Guidelines
Committee, Japan Society of Chemotherapy, Tokyo, Japan
M. Yasuda (&)
Department of Urology, Division of Disease Control,
Research Field of Medical Sciences, Graduate School of
Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan
e-mail: super7@gifu-u.ac.jp
123
J Infect Chemother (2011) 17:579–594
DOI 10.1007/s10156-010-0193-y
. Open access under the Elsevier OA license.
harmonization, there were many challenges due to differ-
ences between Japan and Western countries in the classi-
ﬁcation and diagnosis of UTIs and in the criteria for the
clinical evaluation of drug efﬁcacy and for clinical
response. Moreover, the 4th edition of the Criteria for
Evaluation of Clinical Efﬁcacy of Antimicrobial Agents on
UTI (tentative) was not user-friendly, such that some cli-
nicians suggested that the clinical evaluation of drug efﬁ-
cacy should be simpliﬁed for clinical practice. Based on
these suggestions, we decided to review the Criteria for
Clinical Evaluation of Drug Efﬁcacy on UTI for revision.
The following committee proceeded with the review of
the 4th edition and agreed that a new revised version
should be called the 5th edition of the Criteria for Clinical
Evaluation of Drug Efﬁcacy on UTI. However, when
the committee introduced the outline of the 5th edition at
the 19th symposium on UTI and discussed it among the
members, the majority agreed that the new edition should
be named ‘‘Japanese Guideline for Clinical Research of
Antimicrobial Agents on Urogenital Infections’’. In addi-
tion to creating this guideline, we would like to express
gratitude for the cooperation of the members of the Japa-
nese UTI Research Group, who will be listed later.
Introduction
This guideline aims to objectively evaluate the efﬁcacy of
antimicrobial agents for the treatment of UTIs.
We have made efforts to allow use of the guideline in
both general clinical studies and comparative studies and
objective comparisons of individual study results. We have
established the minimum necessary criteria in the guideline
so that there is allowance to change items when consider-
ing individual cases or according to the practice of each
institution.
General considerations
Target infections
Urological infections are classiﬁed as urinary tract infec-
tions (cystitis, pyelonephritis) and genital infections (ure-
thritis, prostatitis, epididymitis) according to the site of
infection. These infections are non-speciﬁc inﬂammations
caused by common bacteria and are not speciﬁc inﬂam-
mations caused by fungi, Mycobacterium species, viruses,
etc.
Urinary tract infections include acute uncomplicated
cystitis, acute uncomplicated pyelonephritis, and compli-
cated urinary tract infection.
Urinary tract infections are classiﬁed as acute or
chronic according to the clinical course, as uncomplicated
and complicated by the underlying disease, and further, as
cystitis and pyelonephritis by infected site. Generally, the
disease name is based on a combination of the clinical
course, underlying disease, and site of infection. Whereas
uncomplicated urinary tract infections are infections with
no underlying disease that could affect urination. Com-
plicated urinary tract infections of limited sense are
deﬁned as infections with underlying disease that could
affect urination and complicated urinary tract infections
of wider sense are infections with underlying disease
(diabetes, immunosuppression, etc.) that could induce,
exacerbate, and prolong urinary tract infections, in addi-
tion to infections in the limited sense and infections in
men. Complicated urinary tract infections were deﬁned in
the conventional Criteria for Evaluation of Clinical Efﬁ-
cacy of Antimicrobial Agents on UTI as infections with
underlying disease in the urinary tract; namely, compli-
cated urinary tract infections in the limited sense. Con-
sidering the following facts, that: (1) complications such
as diabetes can induce, exacerbate, and prolong urinary
tract infections, as can underlying diseases in the urinary
tract; (2) urinary tract infections are retrograde infections,
so that men tend not to develop retrograde infection
compared with women, in whom the urethra is 10 times
shorter than in men; and (3) even if a male patient is
diagnosed as having no underlying diseases in the urinary
tract, further examination ﬁnds that most male patients
with UTI have underlying diseases, including impaired
urine excretion, we have decided to employ the deﬁnition
of complicated urinary tract infections in the wider sense
in this guideline. It is preferable to exclude from the
guideline patients with urinary diversion using intestinal
segments or those with a catheter, other than a permanent
catheter, because it is difﬁcult to determine the response
of such patients to antimicrobial agents.
Genital infections include urethritis, acute bacterial
prostatitis, and acute epididymitis.
Prostatitis is classiﬁed into four categories according to
clinical condition by the NIH: category I, acute bacterial
prostatitis; category II, chronic bacterial prostatitis; cate-
gory III, chronic pelvic pain syndrome/chronic pain syn-
drome associated with prostatitis (A, inﬂammatory; B,
noninﬂammatory); category IV, asymptomatic prostatitis.
We include only category I; namely, acute bacterial pros-
tatitis, in this guideline because the disease is clearly
associated with bacteria, antimicrobial agents are used for
the treatment of the disease, and it is possible to evaluate
the efﬁcacy of antimicrobial drugs over a relatively short
period. Likewise, regarding epididymitis, we include only
acute epididymitis in the guideline.
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Entry criteria
• Age/sex: Individual diseases are determined. When a
minor is included in the study, a thorough explanation
of the details of the study is given to both the partici-
pant and the participant’s parents or guardians at the
time of agreeing to enter the study.
• Symptoms: This guideline evaluates the efﬁcacy of
antibiotic drugs against urogenital infections. It is
preferable to exclude cases of colonization resulting
from pathogenic microorganisms. Therefore, it was
concluded that the criteria for inclusion in the study
require cases in patients with subjective symptoms that
originate in the urinary tract as a result of urogenital
infection.
• Pyuria: The criteria of pyuria for each disease have
been established. However, the following test methods
may also be used. In addition, when new methods equal
to, or better than, these methods are developed, these
methods will likely be replaced.
– Microscopy of urinary sediment (because 500g 9
5 min is not considered sufﬁcient, it is preferable to
extend the centrifugation time)
– Urinary test strip (the principal measurement is
esterase activity)
– Counting chamber method that uses non-centri-
fuged urine (Kova Slide 10 Grid, HYCOR
Biomedical Inc., Garden Grove, CA)
– Use of ﬂow cytometry with non-centrifuged urine
and a fully automatic urine analysis system is
assumed to be fundamental [equal to or better than
Sysmex UF-50, UF-100, UF110i, UF-1000i
(SYSMEXCorp., Hyogo, Japan), and other systems].
Exclusion criteria
The number of bacteria present is the standard for exclu-
sion. Cases in which the prescribed bacterial count is not
reached are considered contaminated and are excluded
from consideration. The bacterial count for each disease
has been determined.
Targeted bacterial strains
To evaluate the drug efﬁcacy against bacterial strains, patho-
gens originating in the urogenital tract are differentiated from
pathogens present in the urinary tract due to sexually trans-
mitted diseases. However, when the bacterial levels beyond
those already counted exceed the above-mentioned exclusion
criteria, ‘‘acceptance’’ or ‘‘rejection’’ is decided after exam-
ining the details. In addition,when the pathogen type is clearly
understood, it is possible to target that pathogen type.
Dosage period
The standard duration of treatment is assumed to be from a
single dose to 14 days, but this may differ according to the
disease, and it is also determined according to the char-
acteristics of the experimental drug.
Completion of therapy
Basically, the ﬁnal day a dose is given is considered to be
the end of treatment with the experimental drug. However,
when the half-life of a drug has an effective blood and
urine level that continues for a longer period, the day on
which it is estimated that no effective level of the drug is
left in the bloodstream is considered to be the end of
treatment with that drug.
Assessment criteria
Efﬁcacy results
As a rule, the efﬁcacy of the drug will be assessed
5–9 days and 4–6 weeks after completion of therapy.
The principal conclusion on bacteriological efﬁcacy is
made 5–9 days after completion of therapy. This is a
period of time would be needed for remaining bacteria to
re-multiply after the antibiotic is ‘‘washed out’’ of the
body.
Special consideration must be given when a drug with a
long half-life is used in high doses. Furthermore, in cases
of infection by Chlamydia trachomatis and Mycoplasma
genitalium, because it is difﬁcult to culture these micro-
organisms, to avoid amplifying nucleic acid in dead bac-
teria and creating a false-positive reading, the nucleic acid
ampliﬁcation method should be performed 2–4 weeks after
completion of therapy to evaluate bacteriological efﬁcacy
against nongonococcal urethritis.
• Determination of efﬁcacy 5–9 days after completion of
therapy:
– Microbiological outcome (primary endpoint):
Assessments are made as ‘‘Eradication’’ or ‘‘Failure’’
based on total bacterial count. Furthermore, in the
case of ‘‘failure’’, further subclassiﬁcations of ‘‘Per-
sistence’’, ‘‘Replaced’’, and ‘‘Other’’ are included.
– Clinical outcome: Assessments are made as ‘‘Cure’’
or ‘‘Failure’’ based on the presence or absence of
symptoms. Symptoms that appear to be due to
existing underlying disease, etc., before the infec-
tion developed, are not considered.
– Microbiological response according to bacterial
strain: Assessments are made as ‘‘Eradication’’,
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‘‘Persistence’’, or ‘‘Reinfection’’ based on the
results of the urine culture, according to the
bacterial strain: However, if the bacterial strain of
the urinary pathogen cannot be determined, and the
bacterial count is lower than the count required for a
positive reading, the bacterial strain is not consid-
ered signiﬁcant and the response is assessed as
‘‘Eradication’’.
• Assessment of response 4–6 weeks after the end of
treatment:
– Microbiological outcome: Assessments are made as
‘‘Eradication’’ or ‘‘Failure’’ based on total bacterial
count. In the case of ‘‘Failure’’, it is possible to
subclassify this into ‘‘Relapse’’ (the species isolated
is the same as the causative bacterial species) and
‘‘Reinfection’’ (the bacterial strain is different from
the causative bacteria).
– Clinical efﬁcacy: Assessments are made as ‘‘Cure’’
or ‘‘Failure’’ based on the presence or absence of
symptoms.
• Subjective symptoms (Tables 1, 2)
Symptoms are classiﬁed into 4 degrees of severity (as
listed in Tables 1 and 2) and marked on the case report
form. Symptoms related to the target infection should be
examined, but symptoms arising from underlying diseases
are excluded (Table 1).
Refer to the examples listed in Table 2 for classifying
the severity of symptoms.
Urine sampling
Midstream urine samples in males and catheterized urine
(bladder urine) samples in females are preferred, but
midstream urine can also be used in females when obtained
according to the procedures described below. Catheterized
urine should be used for re-examination in cases where
there is some doubt about results from midstream urine.
The method used to obtain the urine sample should be
clearly recorded.
The route and site of indwelling should be noted for
patients with an indwelling catheter. Principally, a closed
drainage system is used and urine is collected by inserting a
needle into the tube, but in open drainage systems, urine
ﬂowing out of the catheter is collected directly after dis-
infecting and cleaning the tip of the catheter.
Procedures for midstream urine sampling
Ambulatory males Wet a cotton sponge or gauze with
cold, warm or soapy water and give it to the patient in the
outpatient clinic.
Procedures
1. Wash hands.
2. Expose the penis.
3. Retract the foreskin from over the glans to expose
the glans in the case of phimosis.
4. Wipe the glans thoroughlywith thewet cottonorgauze.
5. Hold the cup for collecting the urine sample without
touching the inside of the cup, and void the initial
urine into the toilet, putting only midstream urine
into the cup. Void the remaining urine into the toilet
without putting it into the cup.
Essential points
• Use a new cup if the patient touches the inside of a
cup or drops it on the ﬂoor.
• Have the patient tell the doctor when he has difﬁculty
in retracting the foreskin, or when the position of the
external urethral oriﬁce is abnormal.
• If there are problems with the urine sample upon
medical examination, collect another urine sample
after wiping the penis clean. Otherwise collect
catheterized urine.
• Use a lidded cup if possible, covering the cup
immediately after micturition.
Ambulatory females Wet a cotton sponge or gauze with
cold, warm or soapy water and give it to the patient in the
outpatient clinic.
Procedures
1. Wash hands.
2. Lower underpants or panties sufﬁciently or remove
them completely.
3. Open both legs as wide apart as possible.
4. Open the labia with one hand and keep them open
until the urine sample has been obtained.
5. Wipe the area around the urethral oriﬁce (external
urethral oriﬁce) thoroughly with the wet cotton
sponge or gauze.
6. Hold the cup for collecting the urine sample without
touching the inside of the cup, and void the initial
urine into the toilet, putting only midstream urine
into the cup. Void the remaining urine into the toilet
without putting it into the cup.
Table 1 Subjective symptoms
Subjective symptoms
None -
Mild ?
Moderate ??
Severe ???
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Essential points
• Let the patient conﬁrm the urethral oriﬁce by herself
and have her wipe slowly from the front to the back.
• Patients with a lot of hair or those who are obese
should wipe the area around the oriﬁce especially
thoroughly with the wet cotton sponge or gauze.
Table 2 Severity of symptoms
Fever
- Maximum temperature lower than 37.0C
? Maximum temperature 37.0–37.9C
?? Maximum temperature 38.0–38.9C
??? Maximum temperature 39.0C or higher
Dysuria
- No pain
? Slight pain
?? Considerable pain, but tolerable
??? Severe pain requiring treatment
Urgency
- None
? Desire to micturate again, but mostly can wait
?? Desire to micturate again, and often cannot wait
??? Desire to micturate again, and cannot wait
Frequency
- Normal
? More frequent than normal, but can hold for more than 1 h
?? Considerably more frequent than normal, cannot hold even for 1 h. Wakes up at night for
micturition.
??? Very frequent, cannot hold even for 30 min. Wakes up often at night for micturition.
Suprapubic pain
- None
? Occasional pain, but usually overlooked
?? Considerable pain, but tolerable
??? Severe pain requiring treatment
Lumbar pain
- None
? Occasional pain, but usually overlooked
?? Considerable pain, but tolerable
??? Severe pain requiring treatment
Discomfort on micturition
- No discomfort
? Discomfort which quickly passes
?? Discomfort on micturition, but tolerable
??? Discomfort requiring treatment
Lower abdominal discomfort
- None
? Discomfort in the lower abdomen, which quickly passes
?? Discomfort in the lower abdomen, heavy but tolerable
??? Discomfort requiring treatment
Sensation of residual urine
- None
? Discomfort after micturition, which quickly passes
?? Desire to micturate again, but can wait
??? Strong sensation of residuum after micturition requiring treatment
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• Use a new cup if the patient touches the inside of a
cup or drops it on the ﬂoor.
• Use a lidded cup if possible, covering the cup
immediately after micturition.
Bedridden patients Catheterized urine is preferable to
midstream urine for bothmale and female bedridden patients.
Midstream urine samples should be obtained in basically
the same way as in ambulatory patients.
Procedures
Male
1. Expose the penis.
2. Place the bedpan under the patient.
3. Retract the foreskin from over the glans to expose
the glans in the case of phimosis.
4. Wipe the glans thoroughly with the wet cotton or
gauze.
5. Void the initial urine into the bedpan.
6. Put midstream urine into the cup, being careful to
keep the penis from touching the cup.
Female
1. Remove underpants or panties completely.
2. Place the bedpan under the patient.
3. Open both legs and knees as wide apart as possible.
4. Open the labia with one hand and keep them open
until the urine sample has been taken.
5. Wipe the area around the urethral oriﬁce (external
urethral oriﬁce) thoroughly with the wet cotton
sponge or gauze.
6. Void the initial urine into the bedpan.
7. Put midstream urine into the cup.
Acute uncomplicated cystitis
Target infection
Acute uncomplicated cystitis that is considered of bacterial
origin.
Entry criteria
1. Sex/age: Women 16 years of age and older (subgroup
analysis shall be performed separately for postmeno-
pausal cases).
2. Symptoms: Subjective symptoms of dysuria, frequent
urination, urgency, suprapubic pain.
However, in patients without any such symptoms of
cystitis within 4 weeks of this episode.
3. Pyuria: Patients meeting any of the following criteria
before initiation of treatment.
Prescribed equipment using non-centrifuged urine:
C10 WBCs/ll.
Counting chamber method using non-centrifuged
urine: C10 WBCs/mm3.
Urinary test strip that uses non-centrifuged urine
(based on esterase activity determination): Positive.
(However, because of occasional false-negatives,
reconﬁrmation of negative cases by another method
is advisable.)
Microscopy of urinary sediment: C5 WBCs/high-
power ﬁeld (hpf).
Exclusion criteria
Bacterial count: Viable bacterial count before initiation of
medication \103 CFU/mL (\104 CFU/mL in midstream
urine).
Target bacterial strains
The following bacterial species are targeted.
In cases where bacterial strains other than the following
are isolated at C103 CFU/mL (midstream urine C104 CFU/
mL), adoption or rejection shall be judged after examining
details.
Staphylococcus sp.
Enterococcus faecalis
Streptococcus agalactiae
Enterobacteriaceae
Dosage period
The dosage period is from a single dose to 7 days
depending on the characteristics of the drug.
Evaluation of efﬁcacy
1. Timing
Assessment shall be made 5–9 days and 4–6 weeks
after completion of therapy. However, the primary
endpoint shall be the microbiological response
5–9 days after completion of therapy.
2. 5–9 days after completion of therapy (Assessment of
cure) (Tables 3, 4, 5, 6)
(1) Microbiological outcome (primary endpoint)
(Tables 3, 4).
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 3.
Also, ‘‘Failure’’ is divided into subclassiﬁcations of
‘‘Persistence’’, ‘‘Replaced’’, or ‘‘Other’’. (Table 4).
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(2) Clinical outcome (Table 5)
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 5.
(3) Bacteriological response according to bacterial
strains (Table 6).
Assess bacteriological response at 3 levels,
‘‘Eradication’’, ‘‘Persistence’’, and ‘‘Replaced’’,
as listed in Table 6, based on urine culture results
and according to each bacterial strains.
Do not regard bacteria isolated at a total count of
\103 CFU/mL as signiﬁcant but classify the
response as ‘‘Eradication’’.
3. 4–6 weeks after completion of therapy. (Assessment of
recurrence) (Tables 7, 8).
Cases determined bacteriologically as ‘‘Eradication’’
5–9 days after completion of therapy shall be
targeted.
(1) Bacteriological outcome (Table 7)
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 7.
(2) Clinical outcome (Table 8)
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 8.
Table 3 Microbiological outcome for acute uncomplicated cystitis (Assessment of cure)
Eradication Total bacterial count\103 CFU/mL (\104 CFU/mL in midstream urine)
Failure Total bacterial count C103 CFU/mL (C104 CFU/mL in midstream urine),
or changes/additions of antimicrobial agents
Table 4 Subclassiﬁcation of ‘‘Failure’’ for acute uncomplicated cystitis
Persistence The same bacterial strains as those before medication are isolated at C103 CFU/mL
(C104 CFU/mL in midstream urine)
Replaced Only bacterial strains different from those before medication are isolated at C103 CFU/mL
(C104 CFU/mL in midstream urine)
Other Neither ‘‘Persistence’’ nor ‘‘Replaced’’, or changes/additions of antimicrobial agents
Table 5 Clinical outcome for acute uncomplicated cystitis (Assessment of cure)
Cure All subjective symptoms disappeared
Failure Any subjective symptoms remain, or changes/additions
of antimicrobial agents
Table 6 Bacteriological response according to bacterial strains
Eradication Strains found before medication are not found after medication
Persistence Strains found before medication are also isolated after medication
Replaced Strains not found before medication are isolated after medication
Table 7 Bacteriological outcome for acute uncomplicated cystitis (Assessment of recurrence)
Eradication Total bacterial count\103 CFU/mL (\104 CFU/mL in midstream urine)
Failure Total bacterial count C103 CFU/mL (C104 CFU/mL in midstream urine), or changes/additions of
antimicrobial agents Whenever possible, classify as ‘‘Relapse’’ or ‘‘Reinfection’’.
Table 8 Clinical outcome for acute uncomplicated cystitis (Assessment of recurrence)
Cure All subjective symptoms disappeared
Failure Any subjective symptoms remain, symptoms present at onset and absent at assessment of cure
appear again or are exacerbated, or changes/additions of antimicrobial agents
J Infect Chemother (2011) 17:579–594 585
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Acute uncomplicated pyelonephritis
Target infection
Acute uncomplicated pyelonephritis that is considered
bacterial and that is tested within 3 days of onset of this
episode.
Entry criteria
1. Age/sex: Women 16 years of age and older (subgroup
analysis shall be performed separately for postmeno-
pausal cases).
2. Symptoms: Fever of 37.5C or higher, lumbago, ﬂank
pain, or costophrenic angle (CVA) knock pain.
Cases of acute uncomplicated pyelonephritis within
4 weeks before this episode are excluded.
3. Pyuria: Patients with pyuria meeting any of the
following criteria before medication.
Prescribed equipment using non-centrifuged urine:
C10 WBCs/ll.
Counting chamber method using non-centrifuged
urine: C10 WBCs/mm3.
Urinary test strip using non-centrifuged urine (based
on esterase activity determination): Positive.
(Because of occasional false-negatives, reconﬁrmation
of negative cases by another method is advisable.)
Microscopy of urine sediment: C5 WBCs/hpf.
Exclusion criteria
Bacterial count: Total bacterial count before medication
\103 CFU/mL (\104 CFU/mL in midstream urine).
Target bacterial strains
Bacterial strains: The following strains shall be targeted.
In cases where bacterial strains other than the follow-
ing are isolated at C103 CFU/mL (midstream urine
C104 CFU/mL), adoption shall be judged after examining
details.
Staphylococcus sp.
Enterococcus faecalis
Streptococcus agalactiae
Enterobacteriaceae
Dosage periods
Limited to 14-day administration, depending on the char-
acteristics of the drug.
Evaluation of efﬁcacy
1. Timing
Response is assessed 5 to 9 days and 4 to 6 weeks after
completion of therapy. The primary assessment is the
microbiological response 5 to 9 days after completion
of therapy.
2. 5–9 days after the completion of therapy (Assessment
of cure) (Tables 9, 10, 11, 12).
(1) Microbiological outcome (primary endpoint)
(Tables 9, 10).
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 9.
Also, divide ‘‘Failure’’ into any of ‘‘Persistence’’,
‘‘Replaced’’, or ‘‘Other’’ (Table 10).
Table 9 Microbiological outcome for acute uncomplicated pyelonephritis (Assessment of cure)
Eradication Total bacterial count\103 CFU/mL (\104 CFU/mL in midstream urine)
Failure Total bacterial count C103 CFU/mL (C104 CFU/mL in midstream urine),
or changes/additions of antimicrobial agents
Table 10 Subclassiﬁcation of ‘‘Failure’’ for acute uncomplicated pyelonephritis
Persistence The same bacterial strains as those before medication are isolated at C103 CFU/mL (C104 CFU/mL in midstream urine)
Replaced Only bacterial strains different from those before medication are isolated at C103 CFU/mL (C104 CFU/mL in midstream urine)
Other Neither ‘‘Persistence’’ nor ‘‘Replaced’’, or changes/additions of antimicrobial agents
Table 11 Clinical outcome for acute uncomplicated pyelonephritis (Assessment of cure)
Cure All subjective symptoms disappeared
Failure Any subjective symptoms remain, or changes/additions
of antimicrobial agents
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(2) Clinical outcome (Table 11).
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 11.
(3) Bacteriological effects according to bacterial
strains (Table 12).
Assess bacteriological response at 3 levels,
‘‘Eradication’’, ‘‘Persistence’’, and ‘‘Replaced’’,
as listed in Table 12, based on urine culture
results and according to each bacterial strains.
Do not regard bacteria isolated at a total count
of\103 CFU/mL as signiﬁcant but classify the
response as ‘‘Eradication’’.
3. 4–6 weeks after completion of therapy (Assessment of
recurrence) (Tables 13, 14).
Cases determined bacteriologically as ‘‘Eradication’’ 5
to 9 days after completion of therapy shall be targeted.
(1) Bacteriological outcome (Table 13)
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 13.
(2) Clinical outcome (Table 14)
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 14.
Complicated urinary tract infection
Target infection
Patients with expected clinical cure by antimicrobial ther-
apy of complicated urinary tract infection due to indwelling
catheter (pyelonephritis, cystitis).
Entry criteria
1. Age/sex: Males and females 16 years of age and older.
2. Symptoms: Selected symptoms caused by urinary tract
infection.
3. Pyuria: Pyuria before initiation of medication meeting
the following criteria.
Prescribed equipment using non-centrifuged urine:
C10 WBCs/ll.
Counting chamber method using non-centrifuged
urine: C10 WBCs/mm3.
Urinary test strip that uses non-centrifuged urine
(based on esterase activity determination): Positive.
(Because of not a few false-negatives, reconﬁrming
negative cases by another method is advisable.)
Microscopy of urinary sediment: C5 WBCs/hpf.
4. Complications: Patients diagnosed as having urethritis,
prostatitis, and epididymitis are excluded.
Exclusion criteria
Bacterial count: Viable bacterial count before initiation of
medication \104 CFU/mL (however, \105 CFU/mL in
midstream urine in women).
Targeted bacterial strains
Bacterial strains: The following bacterial species shall be
targeted.
In cases where bacterial strains other than the follow-
ing are isolated at C104 CFU/mL (C105 CFU/mL in
Table 12 Bacteriological response according to bacterial strain
Eradication Strains found before medication are not found after medication
Persistence Strains found before medication are also isolated after medication
Replaced Strains not found before medication are isolated after medication
Table 13 Bacteriological outcome for acute uncomplicated pyelonephritis (Assessment of recurrence)
Eradication Total bacterial count\103 CFU/mL (\104 CFU/mL in midstream urine)
Failure Total bacterial count C103 CFU/mL (C104 CFU/mL in midstream urine)
Whenever possible, classify as ‘‘Relapse’’ or ‘‘Reinfection’’
Table 14 Clinical outcome for acute uncomplicated pyelonephritis (Assessment of recurrence)
Cure All subjective symptoms disappeared
Failure Any subjective symptoms remain, symptoms present at onset and absent at
assessment of cure appear again or are exacerbated, or changes/additions
of antimicrobial agents
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midstream urine in women), adoption shall be judged after
examining details.
\Uropathogens[
Staphylococcus sp.
Enterococcus faecalis
Enterococcus faecium
Streptococcus agalactiae
Streptococcus pyogenes
Enterobacteriaceae
Glucose nonfermentable gram-negative rods
Dosage periods
Duration of medication is for 14 days and is determined by
the characteristics of the drug.
Evaluation of efﬁcacy
1. Timing
Evaluation shall be made 5–9 days and 4–6 weeks
after the end of medication. The main evaluation shall
be on bacteriological effects 5–9 days after the end of
medication.
2. 5–9 days after the end of medication (Assesment of
cure) (Tables 15, 16, 17, 18).
(1) Microbiological outcome (primary assessment)
Tables 15, 16).
Assess in 2 levels of ‘‘Eradication’’ and ‘‘Failure’’
according to Table 15.
Also, divide ‘‘Failure’’ into subclassiﬁcations of
‘‘Persistence’’, ‘‘Replaced’’, and ‘‘Other’’ (Table 16).
(2) Clinical outcome (Table 17).
Assess in 2 levels of ‘‘Cure’’ and ‘‘Failure’’
according to Table 17.
(3) Bacteriological effect according to bacterial
strain (Table 18).
Assess bacteriological response at 3 levels,
‘‘Eradication’’, ‘‘Persistence’’, and ‘‘Replaced’’,
as listed in Table 18, based on urine culture
results and according to each bacterial strains.
Do not regard bacteria isolated at a total count of
\104 CFU/mL (\105 CFU/mL in midstream
urine in women) as signiﬁcant but classify the
response as ‘‘Eradication’’.
3. 4–6 weeks after end of medication (Evaluation of
recurrence) (Tables 19, 20).
Cases determined bacteriologically as ‘‘Eradication’’ 5
to 9 days after the end of medication shall be targeted.
(1) Microbiological outcome (Table 19)
Assess at 2 levels, ‘‘Eradication’’ and ‘‘Failure’’,
according to Table 19.
(2) Clinical outcome (Table 20).
Assess at 2 levels, ‘‘Cure’’ and ‘‘Failure’’,
according to Table 20.
Table 15 Microbiological outcome for complicated UTI (Assessment of cure)
Eradication Total bacterial count\104 CFU/mL (\105 CFU/mL in midstream urine in women)
Failure Total bacterial count C104 CFU/mL (C105 CFU/mL in midstream urine in women), or changes/additions
of antimicrobial agents
Table 16 Subclassiﬁcation of ‘‘Failure’’ for complicated UTI
Persistence Bacterial strains the same as those before medication are isolated
Replaced Only bacterial strains different from those before medication are isolated
Other Neither ‘‘Persistence’’ nor ‘‘Replaced’’, or changes/additions of antimicrobial agents
Table 17 Clinical outcome for complicated UTI (Assessment of cure)
Cure All subjective symptoms disappeared, or the degree of symptoms improved to the level before the development of infection
Failure Symptoms remain or did not improve to the level before the development of infection, or changes/additions of antimicrobial agents
Table 18 Bacteriological response according to bacterial strains
Eradication Strains found before medication are not found after medication
Persistence Strains found before medication are also isolated after medication
Replaced Strains not found before medication are isolated after medication
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Male urethritis
Gonococcal urethritis
Target infection
Male urethritis caused by Neisseria gonorrhoeae.
Entry criteria
1. Age/sex: Males aged 16 years or older.
2. Symptoms: Patients with symptoms suspected to be
those of gonococcal urethritis.
3. Microbial test: Patients in whom culture of Neisseria
gonorrhoeae was performed (culture specimen should
be urethral discharge if available, and if unavailable,
ﬁrst-void urine may be used).
Exclusion criteria
Microbial test: Patients in whom the presence of N. gon-
orrhoeae was not conﬁrmed in the culture test of urethral
discharge before medication or ﬁrst-void urine.
Dosage period
Single dose to 7-day administration, depending on the
characteristics of the drug.
Evaluation of efﬁcacy
1. Timing
Response is assessed 5–9 days after completion of
therapy. The primary endpoint is the microbiological
response.
2. Assessment criteria (Tables 21, 22).
(1) Microbiological outcome (primary endpoint)
(Table 21).
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ based on the detection of gonococcus,
as shown in Table 21.
(2) Clinical outcome (Table 22).
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
based on clinical symptom estimation, as shown
in Table 22.
Mixed infection with Chlamydia and Myco-
plasma is excluded from the evaluation.
Nongonococcal urethritis
Target infection
Chlamydia trachomatis urethritis, Mycoplasma genitalium
urethritis.
Table 19 Bacteriological outcome for complicated UTI (Assessment of recurrence)
Eradication Total bacterial count\104 CFU/mL (\105 CFU/mL in midstream urine in women)
Failure Total bacterial count C104 CFU/mL (C105 CFU/mL in midstream urine in women),
or changes/additions of antimicrobial agents
Whenever possible, classify as ‘‘Relapse’’ or ‘‘Reinfection’’
Table 20 Clinical outcome for complicated UTI (Assessment of recurrence)
Cure All subjective symptoms disappeared, or the degree of symptoms improved to the level before the development of infection
Failure Symptoms remain or did not improve to the level before the development of infection, or changes/additions of antimicrobial agents
Table 21 Microbiological outcome for gonococcal urethritis
Eradication Patients with no gonococcus detected by culture
Failure Patients with gonococcus detected by culture, or changes/additions of antimicrobial agents
Table 22 Clinical outcome for gonococcal urethritis
Cure Patients with no symptoms derived from urethritis
Failure Patients with a symptom derived from urethritis, or with changes/additions of antimicrobial agents
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Entry criteria
1. Age/sex: Males aged 16 years or older.
2. Symptoms: Patients with symptoms suspected to be
those of nongonococcal urethritis.
3. Microbial test: C. trachomatis is detected by nucleic
acid ampliﬁcation tests such as transcription mediated
ampliﬁcation (TMA), strand displacement ampliﬁca-
tion (SDA), and polymerase chain reaction (PCR).
M. genitalium is detected by PCR, etc.
(Culture specimen should be urethral discharge if avail-
able, and if unavailable, ﬁrst-void urine may be used.)
Exclusion criteria
1. Patients in whom C. trachomatis or M. genitalium was
not detected from urethral discharge before medication
or ﬁrst-void urine.
2. Patients in whom gonococcus was detected.
Dosage period
Single dose to 14-day administration, depending on the
characteristics of the drug.
Response assessment
1. Timing
Response is assessed 2–4 weeks after completion of
therapy. The primary outcome is the microbiological
response.
2. Assessment criteria (Tables 23, 24)
(1) Microbiological outcome (primary assessment)
(Table 23).
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ based on the detection of C. tracho-
matis or M. genitalium, as shown in Table 23.
(2) Clinical outcome (Table 24)
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
based on the determination of clinical symptoms,
as shown in Table 24.
Acute bacterial prostatitis
Target infection
Acute prostatitis which is considered bacterial in origin
and which is tested within 10 days of onset of this
episode.
Entry criteria
1. Age/sex: Males aged 16 years or older.
2. Symptoms: Fever of 37.5C or higher and dysuria,
clinically regarded as acute bacterial prostatitis.
3. Pyuria: Pyuria (midstream urine) meeting any of the
following criteria before medication.
Prescribed equipment using non-centrifuged urine:
C10 WBCs/ll.
Counting chamber method using non-centrifuged
urine: C10 WBCs/mm3.
Urinary test strip using non-centrifuged urine (based
on esterase activity determination): Positive.
(Because of occasional false-negatives, reconﬁrmation
of negative cases by another method is advisable.)
Microscopy of urine sediment: C5 WBCs/hpf.
Table 23 Microbiological outcome for nongonococcal urethritis
Eradication Patients with no Chlamydia trachomatis or Mycoplasma genitalium detected by nucleic
acid ampliﬁcation testsa
Failure Patients with C. trachomatis or M. genitalium detected by nucleic acid ampliﬁcation testsa,
or changes/additions of antimicrobial agents
M. genitalium is detected by polymerase chain reaction (PCR), etc
a C. trachomatis is detected by nucleic acid ampliﬁcation tests such as transcription mediated ampliﬁcation (TMA), strand displacement
ampliﬁcation (SDA), and PCR
Table 24 Clinical outcome for nongonococcal urethritis
Cure Patients with no symptoms derived from urethritis
Failure Patients with a symptom derived from urethritis, or with
changes/additions of antimicrobial agents
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Exclusion criteria
1. Patients with viable bacterial count in midstream urine
of\104 CFU/mL before medication.
2. Patients with prostate biopsy or catheter placement just
before therapy.
Target bacterial strains
The following strains shall be targeted.
When bacterial species other than the following are
isolated at C104 CFU/mL, adoption shall be judged after
examining details.
\Uropathogens[
Staphylococcus sp.
Enterococcus faecalis
Streptococcus agalactiae
Enterobacteriaceae
Pseudomonas aeruginosa
Dosage period
Oral drugs shall be administered for at least 14 days, but
the dosage period for parenteral drugs shall be determined
depending on the characteristics of the drug.
Response assessment
1. Timing
Response is assessed 5–9 days and 4–6 weeks after
completion of therapy. The primary endpoint is the
microbiological response.
2. 5–9 Days after the completion of therapy (Assessment
of cure) (Tables 25, 26, 27).
(1) Microbiological outcome (primary endpoint)
(Table 25).
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 25.
(2) Clinical outcome (Table 26).
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 26.
(3) Bacteriological effects according to bacterial
strains (Table 27).
Assess bacteriological response at 3 levels,
‘‘Eradication’’, ‘‘Persistence’’, and ‘‘Replaced’’,
as listed in Table 27, based on urine culture
results and according to bacterial strains. Do not
regard bacteria isolated at a total count of
\103 CFU/mL as signiﬁcant but classify the
response as ‘‘Eradication’’.
3. 4–6 Weeks after completion of therapy (Assessment of
Recurrence) (Tables 28, 29).
Cases determined bacteriologically as ‘‘Eradication’’
5–9 days after completion of therapy that underwent
the necessary tests 4–6 weeks after completion of
therapy shall be targeted.
(1) Bacteriological outcome (Table 28).
Assessments are made at 2 levels, similarly to
Evaluation Criteria (Assessment of cure)
5–9 days after completion of therapy.
(2) Clinical outcome (Table 29).
Assessments are made at 2 levels similarly to
Evaluation Criteria (Assessment of cure) 5–9
Days after completion of therapy.
Table 25 Microbiological outcome for acute bacterial prostatitis (Assessment of cure)
Eradication Total bacterial count\104 CFU/mL
Failure Total bacterial count C104 CFU/mL, or
changes/additions of antimicrobial agents
Table 26 Clinical outcome for acute bacterial prostatitis (Assessment of cure)
Cure Fever and dysuria disappeared
Failure Fever and dysuria remain, or changes/additions of antimicrobial agents
Table 27 Bacteriological effects according to bacterial strains
Eradication Strains found before medication are not found after medication
Persistence Strains found before medication are also isolated after medication
Replaced Strains not found before medication are isolated after medication
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Acute epididymitis
Target infection
Bacterial other than C. trachomatis and acute chlamydial
epididymitis.
Entry criteria
1. Age/sex: Males aged 16 years or older.
2. Symptoms/ﬁndings: Patients with enlargement of the
epididymis and pain from acute onset of epididymitis.
Exclusion criteria
Bacterial: Viable bacterial count of\104 CFU/mL in the
ﬁrst-pass urine before initiation of medication.
Chlamydial: Patients with C. trachomatis not detected
in ﬁrst-pass urine or urethral discharge specimen before
medication. Nucleic acid ampliﬁcation methods such as
TMA, SDA, and PCR should be used to detect
C. trachomatis.
Target bacterial strains in the case of bacteria other
than C. trachomatis
The following bacterial species shall be targeted in the case
of bacteria other than C. trachomatis.
When bacterial species other than the following are
isolated at C104 CFU/mL, adoption shall be judged after
examining details.
Staphylococcus sp.
Enterococcus faecalis
Streptococcus agalactiae
Enterobacteriaceae
Haemophilus inﬂuenzae
Pseudomonas aeruginosa
Dosage period
Oral drugs are administered for at least 14 days, and the
dosage periods of injectable drugs are determined by the
characteristics of the drug.
Evaluation of efﬁcacy
1. Timing
Bacterial: Response is assessed 5 to 9 days and 4 to
6 weeks after completion of therapy. The primary
endpoint is the microbiological outcome 5 to 9 days
after completion of therapy.
Chlamydial: Response is assessed 2 to 4 weeks after
completion of therapy.
2. 5–9 days after completion of therapy (Assessment of
cure) (Tables 30, 31, 32).
(Chlamydial: 2–4 weeks after completion of therapy)
(1) Microbiological outcome (primary endpoint)
(Table 30)
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 30.
(2) Clinical outcome (Table 31)
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 31.
(3) Bacteriological effects according to bacterial
strains (acute bacterial epididymitis only)
(Table 32)
Assess bacteriological response at 3 levels,
‘‘Eradication’’, ‘‘Persistence’’, and ‘‘Replaced’’,
as listed in Table 32, based on urine culture
results and according to bacterial strains. Do not
regard bacteria isolated at a total count of
\103 CFU/mL as signiﬁcant but classify the
response as ‘‘Eradication’’.
3. 4–6 weeks after completion of therapy (Assessment of
recurrence) (Tables 33, 34).
Table 28 Bacteriological outcome for acute bacterial prostatitis (Assessment of recurrence)
Eradication Total bacterial count\104 CFU/mL
Failure Total bacterial count C104 CFU/mL, or
changes/additions of antimicrobial agents
Table 29 Clinical outcome for acute bacterial prostatitis (Assessment of recurrence)
Cure Fever and dysuria disappeared
Failure Fever and dysuria remain, or changes/
additions of antimicrobial agents
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Bacterial: The efﬁcacy of the microbiological outcome
is judged 5–9 days after completion of therapy.
Chlamydial: Not determined.
(1) Microbiological outcome (Table 33)
Assessments are made as ‘‘Eradication’’ or
‘‘Failure’’ according to Table 33.
(2) Clinical outcome (Table 34)
Assessments are made as ‘‘Cure’’ or ‘‘Failure’’
according to Table 34.
Appendix
UTI Subcommittee of the Clinical Evaluation
Guidelines Committee, Japan Society of Chemotherapy
Chairman: Tetsuro Matsumoto.
Members: Satoshi Takahashi, Hiroshi Kiyota, Mitsuru
Yasuda, Kiyohito Ishikawa, Akira Takahashi, Shingo
Yamamoto, Soichi Arakawa, Koichi Monden, Tetsuro
Muratani, Ryoichi Hamasuna, and Hiroshi Hayami.
Table 30 Microbiological outcome for acute epididymitis (Assessment of cure)
Eradication
Bacterial Total bacterial count\104 CFU/mL
Chlamydial C. trachomatis is not detectable by culture or other test methods
Failure
Bacterial Total bacterial count C104 CFU/mL, or changes/additions of antimicrobial agents
Chlamydial C. trachomatis is detectable by culture or other test methods, or changes/additions of antimicrobial agents
Table 31 Clinical outcome for acute epididymitis (Assessment of cure)
Cure No symptoms of fever or spontaneous pain derived from epididymitis
Failure Fever and spontaneous pain derived from epididymitis remain, or changes/additions of antimicrobial agents
Table 32 Bacteriological effects according to bacterial strains (Acute bacterial epididymitis only)
Eradication Strains found before medication are not found after medication
Persistence Strains found before medication are also isolated after medication
Replaced Strains not found before medication are isolated after medication
Table 33 Microbiological outcome for acute epididymitis (Assessment of recurrence)
Eradication
Bacterial Total bacterial count\104 CFU/mL
Chlamydial Not determined
Failure
Bacterial Total bacterial count C104 CFU/mL, or changes/additions
of antimicrobial agents
Chlamydial Not determined
Table 34 Clinical outcome for acute epididymitis (Assessment of recurrence)
Cure
Bacterial Acute symptoms of epididymitis disappeared
Chlamydia Not determined
Failure
Bacterial Acute symptoms of epididymitis remain, or changes/additions of antimicrobial agents
Chlamydia Not determined
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Kikuchi, Seiji Naito, Hiroyuki Nomura, Noriyuki Hiraga,
Sojun Kanamaru, Osamu Ogawa, Sadao Kamidono,
Katsumi Shigemura, Kazushi Tanaka, Yuzo Nakano,
Masato Fujisawa, Tetsuya Miura, Yasuharu Kunishima,
Taiji Tsukamoto, Masanori Matsukawa, Yoji Yamada,
Shoichi Onodera, Hiroki Shima, Masanobu Shigeta,
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